Next Article in Journal
Inhibition of Alternative Cancer Cell Metabolism of EGFR Mutated Non-Small Cell Lung Cancer Serves as a Potential Therapeutic Strategy
Previous Article in Journal
Contribution of mTOR and PTEN to Radioresistance in Sporadic and NF2-Associated Vestibular Schwannomas: A Microarray and Pathway Analysis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Erratum

Erratum: Passardi, A. et al. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers 2019, 11, 663

1
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli n. 40, 47014 Meldola, Italy
2
Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli n. 40, 47014 Meldola, Italy
3
Radiotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli n. 40, 47014 Meldola, Italy
4
General and Oncologic Surgery Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Via C. Forlanini n. 34, 47121 Forlì, Italy
5
Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti n. 9, 40138 Bologna, Italy
6
Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli n. 40, 47014 Meldola, Italy
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(1), 178; https://doi.org/10.3390/cancers12010178
Submission received: 16 December 2019 / Accepted: 9 January 2020 / Published: 10 January 2020
The authors wish to make the following corrections to this paper [1]:
The institute name in affiliations 2, 3 and 6 in [1] “IRST-IRCCS” should be written in full, and changed to “Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS”.
The authors would like to apologize for any inconvenience caused to the readers by these changes.

Reference

  1. Passardi, A.; Scarpi, E.; Neri, E.; Parisi, E.; Ghigi, G.; Ercolani, G.; Gardini, A.; La Barba, G.; Pagan, F.; Casadei-Gardini, A.; et al. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers 2019, 11, 663. [Google Scholar] [CrossRef] [PubMed] [Green Version]

Share and Cite

MDPI and ACS Style

Passardi, A.; Scarpi, E.; Neri, E.; Parisi, E.; Ghigi, G.; Ercolani, G.; Gardini, A.; La Barba, G.; Pagan, F.; Casadei-Gardini, A.; et al. Erratum: Passardi, A. et al. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers 2019, 11, 663. Cancers 2020, 12, 178. https://doi.org/10.3390/cancers12010178

AMA Style

Passardi A, Scarpi E, Neri E, Parisi E, Ghigi G, Ercolani G, Gardini A, La Barba G, Pagan F, Casadei-Gardini A, et al. Erratum: Passardi, A. et al. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers 2019, 11, 663. Cancers. 2020; 12(1):178. https://doi.org/10.3390/cancers12010178

Chicago/Turabian Style

Passardi, Alessandro, Emanuela Scarpi, Elisa Neri, Elisabetta Parisi, Giulia Ghigi, Giorgio Ercolani, Andrea Gardini, Giuliano La Barba, Flavia Pagan, Andrea Casadei-Gardini, and et al. 2020. "Erratum: Passardi, A. et al. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers 2019, 11, 663" Cancers 12, no. 1: 178. https://doi.org/10.3390/cancers12010178

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop